CLL/SLL
Clinical trials for CLL/SLL explained in plain language.
Never miss a new study
Get alerted when new CLL/SLL trials appear
Sign up with your email to follow new studies for CLL/SLL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for CLL patients: drug combo aims to wipe out hidden cancer cells
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of targeted therapy will get epcor…
Matched conditions: CLL/SLL
Phase: PHASE2 • Sponsor: Zulfa Omer • Aim: Disease control
Last updated May 26, 2026 06:40 UTC
-
New hope for Tough-to-Treat blood cancers: rocbrutinib takes on pirtobrutinib in Head-to-Head trial
Disease control Recruiting nowThis study tests a new oral drug, rocbrutinib, against another drug, pirtobrutinib, in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or not responded after prior treatment with a BTK inhibitor. About 306 participants …
Matched conditions: CLL/SLL
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated May 26, 2026 06:38 UTC
-
New pill takes on tough blood cancers in early human trial
Disease control Recruiting nowThis early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…
Matched conditions: CLL/SLL
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New hope for CLL patients: drug combo targets relapsed disease
Disease control Recruiting nowThis study tests a combination of two drugs, venetoclax and acalabrutinib, in people with chronic lymphocytic leukemia (CLL) whose cancer returned after initial treatment with venetoclax and an antibody. The goal is to see if this new combo can make the cancer undetectable in the…
Matched conditions: CLL/SLL
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo therapy aims to extend life for blood cancer patients who stopped responding to standard pills
Disease control Recruiting nowThis study tests whether adding a new drug called lisaftoclax to standard BTK inhibitor therapy helps people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. About 400 adults who have been on a BTK inhibit…
Matched conditions: CLL/SLL
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New hope for hard-to-treat blood cancers: experimental drug enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called ZE50-0134 in about 66 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain low-grade lymphomas that have returned or not responded to prior therapies. The main goals are to check the drug's safety and how …
Matched conditions: CLL/SLL
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC